Mississauga, ON -- (SBWIRE) -- 04/04/2014 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Pediapharm Granted Exclusive Commercial Rights for Cuvposa in Canada.”
Companies mentioned in this article include Pediapharm, Inc. (TSX-Venture:PDP).
Sialorrhea, sometimes called hypersalavation, is a persistent drooling problem for many people, probably more than most realize. Saliva is primarily produced from three major salivary glands, the parotid gland, the submandibular gland and the sublingual gland. Sialorrhea can have many causes, such as infection and poisoning, but it is frequently found in people with neurological conditions, such as Parkinson’s disease and cerebral palsy. Suffering from sialorrhea brings with it more than just psychosocial problems as it is surely embarrassing and stigmatizing; it also can lead by physical complications, including perioral chapping, odor and dehydration. The condition can be so difficult to treat, that some patients have to resort to surgery to have one or more salivary glands removed or salivary duct ligation.
Merz Pharmaceuticals, LLC markets Cuvoposa™ for the treatment of sialorrhea in children. Cuvoposa is the only drug approved by the U.S. Food and Drug Administration for the treatment of chronic severe drooling in pediatric patients, aged 3 to 16. North of the U.S. border, Merz Pharma Canada has just granted exclusive commercial rights for Cuvoposa to Pediapharm, Inc. (TSX-Venture:PDP), expanding the specialty pharmaceutical company’s portfolio to seven products.
The full version of this article can be found at:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.